Change in neutrophil-to-lymphocyte ratio during neoadjuvant treatment does not predict pathological response and survival in resectable pancreatic ductal adenocarcinoma Journal Article
| Authors: | Strong, J. S.; Vos, E. L.; McIntyre, C. A.; Chou, J. F.; Gonen, M.; Tang, L. H.; Soares, K. C.; Balachandran, V. P.; Kingham, T. P.; D'Angelica, M. I.; Jarnagin, W. R.; Drebin, J.; Kunstman, J. W.; Allen, P. J.; Wei, A. C. |
| Article Title: | Change in neutrophil-to-lymphocyte ratio during neoadjuvant treatment does not predict pathological response and survival in resectable pancreatic ductal adenocarcinoma |
| Abstract: | Background: Neutrophil-to-lymphocyte ratio (NLR) has been reported as prognostic in pancreatic ductal adenocarcinoma (PDAC). Data about NLR changes during neoadjuvant therapy (NAT) and its relationship with pathological tumor response and survival are lacking. Methods: Pancreatic ductal adenocarcinoma patients with NAT followed by resection between 2009 and 2015 were identified from a prospective database. Neutrophil-to-lymphocyte ratio was collected prior to NAT (baseline), on chemotherapy (prior to cycle 3), and prior to surgery. Baseline NLR, and changes in NLR between baseline and on chemotherapy (delta 1) and between baseline and surgery (delta 2) were compared with pathologic response (<90% and ≥90% defined as poor and good), overall (OS), and disease-free survival (DFS) using Wilcoxon rank-sum and Cox proportional hazard models. Results: Of 93 patients, 17% had good pathological response. Median (interquartile range) NLR at baseline, third cycle, and surgery were 2.7 (2.0-3.7), 2.5 (1.9-4.1), and 3.1 (2.1-5.3), respectively. Median change in NLR from baseline to third cycle was.06 (P =.72), and.6 from baseline to surgery (P <.01). Baseline NLR, delta 1, and delta 2 were not associated with pathological response, OS, or DFS. Discussion: Neutrophil-to-lymphocyte ratio increased after NAT, but a significant association between NLR and pathological response, OS, and DFS in resected PDAC patients was not observed. © The Author(s) 2021. |
| Keywords: | survival; adult; cancer chemotherapy; treatment response; aged; cancer surgery; retrospective studies; major clinical study; overall survival; disease free survival; neoadjuvant therapy; pancreatic neoplasms; antineoplastic agent; adenocarcinoma; multiple cycle treatment; carcinoma, pancreatic ductal; pathology; retrospective study; pancreas carcinoma; neutrophil; pancreas tumor; neutrophils; pancreatic cancer; lymphocyte; lymphocytes; pancreatic ductal adenocarcinoma; pancreatic ductal carcinoma; humans; prognosis; human; male; female; article; neutrophil lymphocyte ratio; neutrophil-to-lymphocyte ratio; pathological tumor response |
| Journal Title: | American Surgeon |
| Volume: | 88 |
| Issue: | 6 |
| ISSN: | 0003-1348 |
| Publisher: | Southeastern Surgical Congress |
| Date Published: | 2022-06-01 |
| Start Page: | 1153 |
| End Page: | 1158 |
| Language: | English |
| DOI: | 10.1177/0003134821989050 |
| PUBMED: | 33517697 |
| PROVIDER: | scopus |
| PMCID: | PMC8501834 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work